Downregulation of stromal syntenin sustains AML development

Area of Science:

• Oncology
• Cell Biology
• Cancer Research

Background:

• Intercellular communication between cancer and stromal cells is crucial for tumor progression.
• Syntenin, a scaffold protein regulating cell communication, is a potential cancer therapeutic target.
• Aggressive acute myeloid leukemia (AML) subtypes are implicated in altering the tumor microenvironment.

Purpose of the Study:

• To investigate the role of syntenin in bone marrow stromal cells (BMSC) in the context of acute myeloid leukemia (AML).
• To elucidate the mechanisms by which stromal syntenin deficiency influences AML aggressiveness.
• To identify potential therapeutic strategies targeting the AML-stroma crosstalk.

Main Methods:

• Serial transplantation of AML cells in mice.
• Co-culture experiments between AML cells and BMSC.
• Analysis of syntenin and endoglin expression levels.
• Assessment of AML cell survival and protein synthesis.

Main Results:

• Aggressive AML reduces syntenin expression in BMSC.
• Syntenin-deficient BMSC promote AML cell survival and protein synthesis, creating a pro-tumoral microenvironment.
• Increased endoglin expression in BMSC, driven by syntenin deficiency, enhances AML translational activity.

Conclusions:

• A signaling loop exists between AML and BMSC, driven by syntenin deficiency and endoglin upregulation.
• Stromal syntenin deficiency promotes AML aggressiveness through enhanced cell survival and protein synthesis.
• Syntenin exhibits tumor-suppressive functions in the AML context, necessitating careful consideration for systemic cancer therapy targeting.